TFII.TO -1.7C -0.17MU -19.63CRWD 5.69PANW 4.39SNOW 16.89V 3.35MAL.TO -0.14
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.21
+0.20 (0.78%)
as of Aug 3, 2026, 1:30:21 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
DON'T BUY

Pfizer Inc(PFE)

Feb 20, 2008
Their pipeline has just not produced new drugs. When you buy this stock now, you are getting a series of cash flows on the existing drugs, but a lot of them are coming off patent. Just acquired a company that has a very small drug, which to him, is a sign of desperation.
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$22.47

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Feb 19, 2008
This is the worst of times for giant pharmaceutical companies. Now spending more on marketing than they are on research/development. Ongoing huge costs of developing new drugs that are safe are a drag. Also, cost of litigation remains a huge burden. Probably safer with the generic companies.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$22.37

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Feb 11, 2008
Has a 2-pronged approach to the drug industry with Teva Pharmaceuticals (TEVA-Q) as his growth generic company and this one as his value dividend play. It is giving great income until their pipeline improves.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$22.20

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Feb 07, 2008
(A Top Pick Feb 1/07. Down 10% including dividends.) This one has been the bane of all value managers. His model price is $37.57, a 66% positive differential. This one needs a catalyst.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$22.67

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 10, 2008
(A Top Pick Dec 18/06. Down 7.4%.) Got decimated when they lost a lawsuit on Lipitor. Sold his holdings.
Photo of David Taylor, MBA, CFADavid Taylor, MBA, CFA
No
Unlock Rating
$24.08

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jan 07, 2008
This sector does well in a slowing economy. 5.6% yield. Has a war chest of almost $30 million in cash to be used for acquisitions. Share buybacks keep increasing the dividends. Mid/long-term pipeline is very promising. Yield and cash limit downside risk. A lot of potential upside surprises.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.23

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Dec 20, 2007
(A Past Top Pick Dec 21/06. Down 10.8%.) This one is probably the bane of all the value managers. Even boosted their dividend by 10%. His model price is $40.53, a 74% positive differential. If they could do anything to thin out that balance sheet, it would be a huge positive for the stock.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$23.22

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 19, 2007
He threw in the towel last quarter and sold his holdings. The problem is they just haven't been developing new drugs and as time goes by, you get closer to patent expiration.
Photo of Charles BobrinskoyCharles Bobrinskoy
No
Unlock Rating
$23.27

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 18, 2007
Big questions with drug companies are “How big is their pipeline of drugs and development?” “What’s the patent life of their big drugs?” and “How vulnerable are they to erosion from generics?”.
Photo of David BaskinDavid Baskin
No
Unlock Rating
$23.37

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Pfizer Inc(PFE)

Dec 12, 2007
Pharma as an industry as a model is really at a crossroads. The chemical-based side is giving way to the biology-side of science. They have a lot of money, but do not have a good pipeline. The biology side is just the opposite. They have the largest phase 2 pipeline that they've ever had and that could translate by 2009 into the biggest phase 3. They own some, but are tempted to pull the plug.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$23.81

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Dec 03, 2007
(A Past Top Pick. Dec 5/06. Down 4.8%.) 5% yield is why he still likes it. All of the bad news is basically known. Sold their consumer products division for $19 billion and will use the cash for acquisitions, share buybacks, dividend increases and increase research. Recession resistant.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$23.55

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Pfizer Inc(PFE)

Nov 30, 2007
It has all the value characteristics that he loves. Has a lot of net cash. Very cheap. Concerned about administration changes when the US election occurs and that their biggest selling drug Lipitor is about 30% of their sales.
Photo of Pat NaccaratoPat Naccarato
No
Unlock Rating
$23.76

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 20, 2007
(A Top Pick Dec 26/06. Down 12.6%.) Still undervalued. Hopefully there’s pressure on management to do something. His model price is $38.27. a 68.5% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$22.72

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Nov 20, 2007
(All 3 Top Picks are defensive, have good dividends, solid earnings and limited downside.) 5% yield and will probably raise the dividend. About $19 billion cash for acquisitions. Drugs that are coming off patent is already built into the stock.
Photo of Norman LevineNorman Levine
Owned
Unlock Rating
$22.72

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 01, 2007
(A Top Pick Dec 21/06. Down 5.6%.) The model price is $42.64, giving it a 73% positive differential.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$23.95

Stock price when the opinion was issued

$24.98

As of Aug 03, 2026. Market Open.

biotechnologypharmaceutical
Showing 541 to 555 of 885 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG -2.68$146.01
SLB -1.22$48.37
SHEL -0.8$91.18
AAPL -2.76$306.15
AMZN 12.495$284.075

Today's Top Picks

TFII.TO -1.7$13.38
C -0.17$132.28
MU -19.63$803.4
CRWD 5.69$196.55
PANW 4.39$336.22

Popular Articles

Latest Sell Signals

AAPL -2.76$306.15
AAPL -2.76$306.15
AAPL -2.76$306.15
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like